Pattern of hormone receptor status of secondary contralateral breast cancers in patients receiving adjuvant tamoxifen

Clinical Cancer Research

Volumn 8, Issue 11, 2002, Pages 3427-3432

  Bachleitner Hofmann, Thomas ^a   Pichler Gebhard, Barbara ^a   Rudas, Margarethe ^a   Gnant, Michael ^a   Taucher, Susanne ^a   Kandioler, Daniela ^a   Janschek, Elisabeth ^a   Dubsky, Peter ^a   Roka, Sebastian ^a   Sporn, Emanuel ^a   Jakesz, Raimund ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; HORMONE RECEPTOR; TAMOXIFEN; PROGESTERONE RECEPTOR;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GRADING; CLINICAL ARTICLE; FEMALE; GROWTH REGULATION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MUTATION; PRIORITY JOURNAL; TUMOR ESCAPE; TUMOR VOLUME; BIOSYNTHESIS; BREAST TUMOR; METASTASIS; MIDDLE AGED; PATHOLOGY; SECOND CANCER; TIME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MUTATION; NEOPLASMS, SECOND PRIMARY; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAMOXIFEN; TIME FACTORS;

EID: 0036847723     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Broet, P., de la Rochefordiere, A., Scholl, S. M., Fourquet, A., Mosseri, V., Durand, J. C., Pouillart, P., and Asselain, B. Contralateral breast cancer: Annual incidence and risk parameters. J. Clin. Oncol., 13: 1578-1583, 1995.
2. Kilgore, A. R. The incidence of cancer in the second breast. J. Am. Med. Assoc., 77: 454-457, 1921.
3. Janschek, E., Kandioler Eckersberger, D., Ludwig, C., Kappel, S., Wolf, B., Taucher, S., Rudas, M., Gnant, M., and Jakesz, R. Contralateral breast cancer: Molecular differentiation between metastasis and second primary cancer. Breast Cancer Res Treat., 67: 1-8, 2001.
4. Healey, E. A., Cook, E. F., Orav, E. J., Schnitt, S. J., Connolly, J. L., and Harris, J. R. Contralateral breast cancer: Clinical characteristics and impact on prognosis. J. Clin. Oncol., 11: 1545-1552, 1993.
5. Coradini, D., Oriana, S., Mariani, L., Miceli, R., Bresciani, G., Marubini, E., and Di Fronzo, G. Is steroid receptor profile in contralateral breast cancer a marker of independence of the corresponding primary tumour? Eur. J. Cancer, 34: 825-830, 1998.
6. Dawson, L. A., Chow, E., and Goss, P. E. Evolving perspectives in contralateral breast cancer. Eur. J. Cancer, 34: 2000-2009, 1998.
7. Raabe, N. K., Sauer, T., Erichsen, A., Nesland, J. M., and Fossaa, S. D. Breast cancer in the contralateral breast: Incidence and histopathology after unilateral radical treatment of the first breast cancer. Oncol Rep., 6: 1001-1007, 1999.
8. Chen, Y., Thompson, W., Semenciw, R., and Mao, Y. Epidemiology of contralateral breast cancer. Cancer Epidemiol. Biomark. Prev., 8: 855-861, 1999.
9. Horn, P. L., and Thompson, W. D. Risk of contralateral breast cancer. Associations with histologic, clinical, and therapeutic factors. Cancer (Phila.), 62: 412-424, 1988.
10. Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., Daly, M., Wieand, S., Tan Chiu, E., Ford, L., and Wolmark, N. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J. Natl. Cancer Inst. (Bethesda), 90: 1371-1388, 1998.
11. Jakesz, R., Hausmaninger, H., and Samonigg, H. Chemotherapy versus hormonal adjuvant treatment in premenopausal patients with breast cancer. Eur. J. Cancer, 38: 327-332, 2002.
12. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet, 351: 1451-1467, 1998.
13. Robinson, E., Kimmick, G. G., and Muss, H. B. Tamoxifen in postmenopausal women a safety perspective. Drugs Aging., 8: 329-337, 1996.
14. Early Breast Cancer Trialists' Collaborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28, 896 women. N. Engl. J. Med., 319: 1681-1692, 1988.
15. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet. 339: 1-15, 1992.
16. Rutqvist, L. E., Johansson, H., Signomklao, T., Johansson, U., Fornander, T., and Wilking, N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. J. Natl. Cancer Inst. (Bethesda), 87: 645-651, 1995.
17. Fisher, B., Costantino, J., Redmond, C., Poisson, R., Bowman, D., Couture, J., Dimitrov, N. V., Wolmark, N., Wickerham, D. L., Fisher, E. R., Margolese, R. G., Robidoux, A., Shibata, H., Terz, J., Paterson, A. H. G., Feldman, M. I., Farrar, W., Evans, J., Lickley, H. L., and Ketner, M. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N. Engl. J. Med., 320: 479-484, 1989.
18. Fisher, B., Dignam, J., Bryant, J., DeCillis, A., Wickerham, D. L., Wolmark, N., Costantino, J., Redmond, C., Fisher, E. R., Bowman, D. M., Deschenes, L., Dimitrov, N. V., Margolese, R. G., Robidoux, A., Shibata, H., Terz, J., Paterson, A. H., Feldman, M. I., Farrar, W., Evans, J., and Lickley, H. L. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J. Natl. Cancer Inst. (Bethesda), 88: 1529-1542, 1996.
19. Lien, E. A., and Lonning, P. E. Selective oestrogen receptor modifiers (SERMs) and breast cancer therapy. Cancer Treat Rev., 26: 205-227, 2000.
20. MacGregor, J. I., and Jordan, V. C. Basic guide to the mechanisms of antiestrogen action. Pharmacol. Rev., 50: 151-196, 1998.
21. Lonning, E., and Lien, E. A. Mechanisms of action of endocrine treatment in breast cancer. Crit. Rev. Oncol. Hematol., 21: 158-193, 1995.
22. Kuukasjarvi, T., Kononen, J., Helin, H., Holli, K., and Isola, J. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J. Clin. Oncol., 14: 2584-2589, 1996.
23. Jordan, V. C. Molecular mechanisms of antiestrogen action in breast cancer. Breast Cancer Res. Treat., 31: 41-52, 1994.
24. Johnston, S. R., Saccani Jotti, G., Smith, I. E., Salter, J., Newby, J., Coppen, M., Ebbs, S. R., and Dowsett, M. Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res., 55: 3331-3338, 1995.
25. Bloom, H. J. G., and Richardson, W. W. Histologic grading and prognosis in breast cancer. Br. J. Cancer, 11: 359-377, 1957.
26. Rudas, M., Neumayer, R., Gnant, M. F., Mittelbock, M., Jakesz, R., and Reiner, A. p53 protein expression, cell proliferation and steroid hormone receptors in ductal and lobular in situ carcinomas of the breast. Eur. J. Cancer, 33: 39-44, 1997.
27. Reiner, A., Neumeister, B., Spona, J., Reiner, G., Schemper, M., and Jakesz, R. Immunocytochemical localization of estrogen and progesterone receptor and prognosis in human primary breast cancer. Cancer Res., 50: 7057-7061, 1990.
28. Rutqvist, L. E., Cedermark, B., Glas, U., Mattsson, A., Skoog, L., Somell, A., Theve, T., Wilking, N., Askergren, J., Hjalmar, M. L., Rotstein, S., Perbeck, L., and Ringborg, U. Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy. J. Natl. Cancer Inst. (Bethesda), 83: 1299-1306, 1991.
29. Li, C. I., Malone, K. E., Weiss, N. S., and Daling, J. R. Tamoxifen therapy for primary breast cancer and risk of contralateral breast cancer. J. Natl. Cancer Inst. (Bethesda), 93: 1008-1013, 2001.
30. Tonetti, D. A., and Jordan, V. C. The role of estrogen receptor mutations in tamoxifen-stimulated breast cancer. J. Steroid Biochem. Mol. Biol., 62: 119-128, 1997.
31. Legault Poisson, S., Jolivet, J., Poisson, R., Beretta Piccoli, M., and Band, P. R. Tamoxifen-induced tumor stimulation and withdrawal response. Cancer Treat. Rep., 63: 1839-1841, 1979.
32. Howell, A., Dodwell, D. J., Anderson, H., and Redford, J. Response after withdrawal of tamoxifen and progestogens in advanced breast cancer. Ann. Oncol., 3: 611-617, 1992.
33. Canney, P. A., Griffiths, T., Latief, T. N., and Priestman, T. J. Clinical significance of tamoxifen withdrawal response. Lancet, 1: 36, 1987.
34. Belani, C. P., Pearl, P., Whitley, N. O., and Aisner, J. Tamoxifen withdrawal response. Report of a case. Arch. Intern. Med., 149: 449-450, 1989.
35. Gottardis, M. M., Jiang, S. Y., Jeng, M. H., and Jordan, V. C. Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res., 49: 4090-4093, 1989.
36. Gottardis, M. M., and Jordan, V. C. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res., 48: 5183-5187, 1988.
37. Lee, E. S., Schafer, J. M., Yao, K., England, G., O'Regan, R. M., De Los Reyes, A., and Jordan, V. C. Cross-resistance of triphenylethylene-type antiestrogens but not ICI 182,780 in tamoxifen-stimulated breast tumors grown in athymic mice. Clin. Cancer Res., 6: 4893-4899, 2000.
38. Schafer, J. M., Lee, E. S., Dardes, R. C., Bentrem, D., O'Regan, R. M., De Los Reyes, A., and Jordan, V. C. Analysis of cross-resistance of the selective estrogen receptor modulators arzoxifene (LY353381) and LY117018 in tamoxifen-stimulated breast cancer xenografts. Clin. Cancer Res., 7: 2505-2512, 2001.
39. Schafer, J. M., Lee, E. S., O'Regan, R. M., Yao, K., and Jordan, V. C. Rapid development of tamoxifen-stimulated mutant p53 breast tumors (T47D) in athymic mice. Clin. Cancer Res., 6: 4373-4380, 2000.
40. Yao, K., Lee, E. S., Bentrem, D. J., England, G., Schafer, J. I., O'Regan, R. M., and Jordan, V. C. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clin. Cancer Res., 6: 2028-2036, 2000.
41. Fuqua, S. A. Estrogen receptor mutagenesis and hormone resistance. Cancer (Phila.), 74: 1026-1029, 1994.
42. Fuqua, S. A., Chamness, G. C., and McGuire, W. L. Estrogen receptor mutations in breast cancer. J. Cell. Biochem., 51: 135-139, 1993.
43. Fuqua, S. A., Fitzgerald, S. D., Chamness, G. C., Tandon, A. K., McDonnell, D. P., Nawaz, Z., O'Malley, B. W., and McGuire, W. L. Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res., 51: 105-109, 1991.
44. Karnik, P. S., Kulkarni, S., Liu, X. P., Budd, G. T., and Bukowski, R. M. Estrogen receptor mutations in tamoxifen-resistant breast cancer. Cancer Res., 54: 349-353, 1994.
45. Zhang, Q. X., Borg, A., Wolf, D. M., Oesterreich, S., and Fuqua, S. A. An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer. Cancer Res., 57: 1244-1249, 1997.
46. Muss, H. B., Thor, A. D., Berry, D. A., Kute, T., Liu, E. T., Koerner, F., Cirrincione, C. T., Budman, D. R., Wood, W. C., Barcos, M., and Henderson, I. C. N. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N. Engl. J. Med., 330: 1260-1266, 1994.
47. Carlomagno, C., Perrone, F., Gallo, C., De Laurentiis, M., Lauria, R., Morabito, A., Pettinato, G., Panico, L., D'Antonio, A., Bianco, A. R., and De Placido, S. c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J. Clin. Oncol., 14: 2702-2708, 1996.
48. Houston, S. J., Plunkett, T. A., Barnes, D. M., Smith, P., Rubens, R. D., and Miles, D. W. Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br. J. Cancer, 79: 1220-1226, 1999.
49. Yamauchi, H., O'Neill, A., Gelman, R., Carney, W., Tenney, D. Y., Hosch, S., and Hayes, D. F. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J. Clin. Oncol., 15: 2518-2525, 1997.
50. Leitzel, K., Teramoto, Y., Konrad, K., Chinchilli, V. M., Volas, G., Grossberg, H., Harvey, H., Demers, L., and Lipton, A. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J. Clin. Oncol., 13: 1129-1135, 1995.
51. Berry, D. A., Muss, H. B., Thor, A. D., Dressler, L., Liu, E. T., Broadwater, G., Budman, D. R., Henderson, I. C., Barcos, M., Hayes, D., and Norton, L. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. J. Clin. Oncol., 18: 3471-3479, 2000.
52. Cancer Res. Campaign Breast Cancer Trials Group. The effect of adjuvant tamoxifen: The latest results from the Cancer Research Campaign Adjuvant Breast Trial. Eur. J. Cancer, 28a: 904-907, 1992.